"MAP Kinase Kinase 1" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
An abundant 43-kDa mitogen-activated protein kinase kinase subtype with specificity for MITOGEN-ACTIVATED PROTEIN KINASE 1 and MITOGEN-ACTIVATED PROTEIN KINASE 3.
| Descriptor ID |
D048369
|
| MeSH Number(s) |
D08.811.913.696.620.682.700.565.100 D08.811.913.696.620.682.725.200.100 D12.644.360.440.100 D12.776.476.440.100
|
| Concept/Terms |
MAP Kinase Kinase 1- MAP Kinase Kinase 1
- MKK1 Protein Kinase
- MAP2K1 Protein
- Mitogen-Activated Protein Kinase Kinase 1
- Mitogen Activated Protein Kinase Kinase 1
- MKK-1 Protein Kinase
- MKK 1 Protein Kinase
- MEK-1 Protein Kinase
- MEK 1 Protein Kinase
- MAPK Kinase 1
- MEK1 Protein Kinase
|
Below are MeSH descriptors whose meaning is more general than "MAP Kinase Kinase 1".
Below are MeSH descriptors whose meaning is more specific than "MAP Kinase Kinase 1".
This graph shows the total number of publications written about "MAP Kinase Kinase 1" by people in this website by year, and whether "MAP Kinase Kinase 1" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1999 | 0 | 2 | 2 |
| 2001 | 0 | 1 | 1 |
| 2002 | 0 | 1 | 1 |
| 2003 | 0 | 1 | 1 |
| 2005 | 0 | 3 | 3 |
| 2007 | 1 | 0 | 1 |
| 2010 | 0 | 3 | 3 |
| 2011 | 0 | 2 | 2 |
| 2012 | 3 | 0 | 3 |
| 2013 | 0 | 2 | 2 |
| 2014 | 1 | 2 | 3 |
| 2015 | 1 | 1 | 2 |
| 2017 | 1 | 0 | 1 |
| 2018 | 1 | 0 | 1 |
| 2019 | 1 | 0 | 1 |
| 2020 | 2 | 1 | 3 |
| 2021 | 3 | 0 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "MAP Kinase Kinase 1" by people in Profiles.
-
Constitutive activation of mitogen-activated protein kinase kinase (MEK1) in ileal enterocytes leads to dysplasia and a predisposition to cancer. Am J Physiol Gastrointest Liver Physiol. 2021 03 01; 320(3):G366-G379.
-
BRAFV 600E or mutant MAP2K1 human CD34+ cells establish Langerhans cell-like histiocytosis in immune-deficient mice. Blood Adv. 2020 10 13; 4(19):4912-4917.
-
MEK activation modulates glycolysis and supports suppressive myeloid cells in TNBC. JCI Insight. 2020 08 06; 5(15).
-
Anti-tumor and anti-metastasis efficacy of E6201, a MEK1 inhibitor, in preclinical models of triple-negative breast cancer. Breast Cancer Res Treat. 2019 Jun; 175(2):339-351.
-
Biological and clinical significance of somatic mutations in Langerhans cell histiocytosis and related histiocytic neoplastic disorders. Hematology Am Soc Hematol Educ Program. 2015; 2015:559-64.
-
Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis. Blood. 2014 Nov 06; 124(19):3007-15.
-
A high content clonogenic survival drug screen identifies mek inhibitors as potent radiation sensitizers for KRAS mutant non-small-cell lung cancer. J Thorac Oncol. 2014 Jul; 9(7):965-973.
-
N-cadherin/FGFR promotes metastasis through epithelial-to-mesenchymal transition and stem/progenitor cell-like properties. Oncogene. 2014 Jun 26; 33(26):3411-21.
-
BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma. Clin Cancer Res. 2013 Mar 01; 19(5):1225-31.
-
MEK inhibitor PD0325901 significantly reduces the growth of papillary thyroid carcinoma cells in vitro and in vivo. Mol Cancer Ther. 2010 Jul; 9(7):1968-76.